Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro susceptibility testing with tobramycin.

S Shadomy, C Kirchoff

    Antimicrobial Agents and Chemotherapy
    |May 1, 1972
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    COVID-19 Vaccine Acceptance Among Latino/a Immigrants: The Role of Collective Responsibility and Confidence.

    Journal of immigrant and minority health·2023
    Same author

    Synergising tools for capacity assessment and One Health operationalisation.

    Revue scientifique et technique (International Office of Epizootics)·2019
    Same author

    Standardized susceptibility testing of fluconazole: an international collaborative study.

    Antimicrobial agents and chemotherapy·1992
    Same author

    Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

    Journal of clinical microbiology·1991
    Same author

    Agar disk diffusion susceptibility tests with cilofungin (LY 121019).

    Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology·1991
    Same author

    Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.

    Diagnostic microbiology and infectious disease·1991

    Tobramycin, an aminoglycoside antibiotic, shows high effectiveness against Staphylococcus aureus and Pseudomonas species. Susceptibility testing of 191 bacterial isolates determined optimal disc diffusion breakpoints for this important antimicrobial.

    Area of Science:

    • Clinical Microbiology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Tobramycin is an aminoglycoside antibiotic with known in vitro activity against Gram-negative bacteria and Staphylococcus aureus.
    • Evaluating the susceptibility of contemporary clinical isolates is crucial for guiding antibiotic therapy.
    • Standardized methods are essential for reproducible antimicrobial susceptibility testing (AST).

    Purpose of the Study:

    • To determine the in vitro activity of tobramycin against a panel of recently isolated pathogenic bacteria.
    • To compare routine broth dilution with the FDA standardized disc diffusion technique for tobramycin susceptibility testing.
    • To establish a reliable zone diameter breakpoint for predicting tobramycin susceptibility using the disc diffusion method.

    Main Methods:

    Related Experiment Videos

    • Susceptibility testing of 191 bacterial isolates (including Escherichia, Enterobacter, Klebsiella, Proteus, Pseudomonas, Serratia, S. aureus, and enterococci) to tobramycin.
    • Utilized both broth dilution and the Food and Drug Administration (FDA) standardized 10-mug disc diffusion technique.
    • Correlated zone of inhibition diameters with minimal inhibitory concentrations (MICs).

    Main Results:

    • Tobramycin demonstrated potent activity against Staphylococcus aureus and Pseudomonas species, with most isolates inhibited by ≤0.20 µg/mL.
    • Moderate activity was observed against Escherichia and Proteus (MIC ≤1.56 µg/mL), with slightly less activity against Klebsiella and Enterobacter.
    • Serratia and enterococci exhibited lower susceptibility.
    • A zone diameter of 16 mm was identified as the critical breakpoint for predicting tobramycin susceptibility via disc diffusion.

    Conclusions:

    • Tobramycin is highly effective against S. aureus and Pseudomonas, making it a valuable therapeutic option.
    • The FDA standardized disc diffusion method is a reliable tool for assessing tobramycin susceptibility.
    • A 16 mm zone diameter breakpoint provides a practical criterion for clinical laboratories to predict tobramycin efficacy.